Other

Acquisition options

Edwards Lifesciences Acquisition options decreased by 37.0% to $79.30M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 47.2%, from $150.30M to $79.30M. Over 2 years (FY 2023 to FY 2025), Acquisition options shows a downward trend with a -11.7% CAGR.

Analysis

StatementBalance Sheet Statement
SectionOther
First reportedQ4 2023
Last reportedQ1 2026
Metric ID: other_acquisition_options_noncurrent

Historical Data

10 periods
 Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$161.30M$172.10M$176.90M$117.50M$147.10M$150.30M$111.50M$129.90M$125.90M$79.30M
QoQ Change—+6.7%+2.8%-33.6%+25.2%+2.2%-25.8%+16.5%-3.1%-37.0%
YoY Change————-8.8%-12.7%-37.0%+10.6%-14.4%-47.2%
Range$79.30M – $176.90M
CAGR-27.1%
Avg YoY Growth-18.3%
Median YoY Growth-13.5%
Current Streak2 quarters decline

Frequently Asked Questions

What is Edwards Lifesciences's acquisition options?
Edwards Lifesciences (EW) reported acquisition options of $79.30M in Q1 2026.
How has Edwards Lifesciences's acquisition options changed year-over-year?
Edwards Lifesciences's acquisition options decreased by 47.2% year-over-year, from $150.30M to $79.30M.
What is the long-term trend for Edwards Lifesciences's acquisition options?
Over 2 years (2023 to 2025), Edwards Lifesciences's acquisition options has grown at a -11.7% compound annual growth rate (CAGR), from $161.30M to $125.90M.